glp 1 kidney disease GLP-1 agonists in the treatment of chronic in type 2 diabetes and obesity Recommendations for SGLT2i versus GLP-1
Description
doi: 10.1177/1759720x241271886
Preclinical studies indicate that GLP-1 RAs can attenuate atherosclerosis by reducing vascular inflammation, lowering oxidative stress, and inhibiting the proliferation and activation of vascular smooth muscle cells [51, 52]
Clinical studies provide strong evidence of their benefits
Given that GLP-1 receptor agonists are revolutionizing the treatment of obesity, we thought it would be an excellent drug to evaluate for potential protective effects against obesity-related cancers
Other Insurance Coverage Guides Not on Aetna
